恩格列净改善肥厚型心肌病小鼠模型代谢效率及左室肥厚
该研究在携带肌球蛋白R403Q突变的雄性小鼠中给予恩格列净治疗16周,采用多核磁共振波谱、超声心动图及组学分析评估代谢、结构与功能变化。结果显示恩格列净促进糖酵解与葡萄糖氧化偶联、正常化细胞内钠水平,显著减轻左室肥厚和心肌纤维化,并改善舒张功能与收缩储备,机制与下调mTOR信号通路及正常化心肌底物代谢流相关。
要点
- 恩格列净减轻HCM小鼠左室肥厚和心肌纤维化
- 恩格列净改善舒张功能与收缩储备
- 机制涉及纠正糖代谢偶联、钠稳态及下调mTOR通路
核心结论
- 恩格列净显著缓解HCM小鼠模型的结构与代谢功能障碍,提示其作为HCM治疗药物的潜力。
- 研究提示SGLT2i在包括心肌特异性突变所致心血管疾病中具有更广泛应用前景,需进一步临床研究。
研究设计与样本
- 携带肌球蛋白R403Q突变的雄性小鼠接受恩格列净治疗16周。
- 采用31P、13C和23Na多核磁共振波谱、超声心动图及转录组、蛋白质组和磷酸化蛋白质组分析评估代谢、结构和功能变化。
主要发现
- 恩格列净促进糖酵解与葡萄糖氧化偶联并正常化升高的细胞内钠水平。
- 超声心动图和病理学显示恩格列净治疗显著减轻左室肥厚和心肌纤维化。
- 结构改善与线粒体ATP合成、脂肪酸氧化及支链氨基酸分解代谢增强相关。
- 恩格列净改善左室舒张功能和收缩储备,表现为ATP产生改善和收缩能量消耗降低。
- 上述获益与mTOR信号通路下调和心肌底物代谢流正常化相关。
临床怎么用
- 目前证据仅来自HCM小鼠模型,尚不能直接指导临床用药。
- 恩格列净在HCM患者中的疗效与安全性需进一步临床试验验证。
局限性
- 研究为小鼠模型,结果不能直接外推至人类HCM患者。
- 仅使用雄性小鼠,未评估性别差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and impaired metabolic efficiency. This study investigates the therapeutic potential of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin (EMPA) in ameliorating these pathological features in a mouse model carrying the myosin R403Q mutation. METHODS: Male mice harbouring the R403Q mutation were treated with EMPA for 16 weeks. Multi-nuclear magnetic resonance spectroscopy (31P, 13C, and 23Na MRS), echocardiography, transcriptomic, proteomic, and phosphoproteomic profiling were utilized to assess metabolic, structural, and functional changes. RESULTS: Empagliflozin facilitated the coupling of glycolysis with glucose oxidation and normalized elevated intracellular sodium levels. Treatment resulted in a significant reduction in LVH and myocardial fibrosis as evidenced by echocardiography and histopathology. These structural improvements correlated with enhancements in mitochondrial adenosine triphosphate (ATP) synthesis, fatty acid oxidation, and branched-chain amino acid catabolism. Furthermore, EMPA improved left ventricular diastolic function and contractile reserve, underscored by improved ATP production and reduced energy cost of contraction. Notably, these benefits were linked to down-regulation of the mammalian target of rapamycin signalling pathway and normalization of myocardial substrate metabolic fluxes. CONCLUSIONS: Empagliflozin significantly mitigates structural and metabolic dysfunctions in a mouse model of HCM, underscoring its potential as a therapeutic agent for managing this condition. These findings suggest broader applicability of SGLT2i in cardiovascular diseases, including those due to myocardial-specific mutations, warranting further clinical investigation.
引用
- Baka T, Moore J, Qin F, et al. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. Eur Heart J. 2025. PMID: 40396194. doi:10.1093/eurheartj/ehaf324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。